The BioPharm Brief: Alzheimer's Advances, Bispecific Innovation, and a New TED Therapy

Jun 29, 08:23 PM
Headliner
Share
Subscribe

Eisai highlights next-generation Alzheimer's research, Talawar Therapeutics secures $285 million to advance a first-in-class bispecific antibody, and the FDA approves a new biologic for thyroid eye disease.

Share
Subscribe
Next
The BioPharm Brief: Priority Review, ADC Progress, and New Frontiers in Fibrosis
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief